Key points from article :
Oral gold nanocrystals (CNM-Au8) show promise in treating multiple sclerosis and Parkinson’s disease in phase 2 trials.
Age and neurodegenerative diseases reduce crucial brain energy metabolite NAD+.
Gold nanocrystals act like catalysts, converting NADH to NAD+, increasing both and potentially improving energy.
Participants with MS & Parkinson's received 120 ml of CNM-Au8, produced by Clene Nanomedicine.
Both groups showed a 10.4% average increase in NAD+/NADH ratio, suggesting the drug targeted the brain.
Parkinson's patients saw significant motor improvement at week 4.
Most side effects were mild and unrelated to the drug, like sinusitis and common cold.
Further research is needed to confirm treatment effectiveness in larger phase 3 trials.
Study by UT Southwestern Medical Center, published in the Journal of Nanobiotechnology.
